These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29861603)

  • 21. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
    Shergold AL; Millar R; Nibbs RJB
    Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.
    Zhang M; Liu K; Wang M
    RSC Adv; 2019 Oct; 9(58):33903-33911. PubMed ID: 35528929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational combination of immunotherapy for triple negative breast cancer treatment.
    Li CW; Lim SO; Hsu JL; Hung MC
    Chin Clin Oncol; 2017 Oct; 6(5):54. PubMed ID: 29129094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.
    Tian T; Li Z
    Front Oncol; 2021; 11():731175. PubMed ID: 34631560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.
    Lin W; Chen M; Hong L; Zhao H; Chen Q
    Front Oncol; 2018; 8():532. PubMed ID: 30519541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
    Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
    Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
    Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
    Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival.
    Krcik EM
    Radiol Technol; 2016 Sep; 88(1):123-8. PubMed ID: 27601709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the programmed cell death-1 pathway in breast and ovarian cancer.
    Emens LA; Kok M; Ojalvo LS
    Curr Opin Obstet Gynecol; 2016 Apr; 28(2):142-7. PubMed ID: 26881392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer.
    Cai J; Qi Q; Qian X; Han J; Zhu X; Zhang Q; Xia R
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1377-1385. PubMed ID: 30963235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
    Gibbons Johnson RM; Dong H
    Front Immunol; 2017; 8():961. PubMed ID: 28848559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
    Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
    J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.